SEC Form 4 · accession 0001209191-16-155526
ARROWHEAD PHARMACEUTICALS, INC. · ARWR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Richard Anzalone
Officer — Chief Executive Officer · Director
Period of report
Dec 13, 2016
Accepted (ET)
Dec 15, 2016 · 9:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000879407
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 13, 2016 | F | 300,444 | $1.27 | D | 816,789 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This disposition reflects the payment of tax liability by withholding shares incident to the vesting of restricted stock units previously granted.